India, Aug. 3 -- NewcelX Ltd. (NCEL), a clinical-stage biopharmaceutical company, reported entering securities purchase agreements for a private placement at $4.033 per share.
The company plans to sell 347,134 common shares and one series of warrants to purchase 347,134 common shares at $4.437 per share.
The offering is expected to include participation from existing shareholders and is scheduled to close on or around August 14, 2026.
The net proceeds from the offering and a previously acquired $25 million equity line is planned to be directed toward working capital, general corporate purposes, and for advancing NCEL-101, a therapy for type-1 diabetes developed in collaboration with Eledon Pharmaceuticals.
googletag.cmd.push(function() ...